• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

    2/14/24 7:43:11 AM ET
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XENE alert in real time by email
    SC 13G/A 1 schedule13g.htm


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.  2 )*

    Xenon Pharmaceuticals Inc.
    (Name of Issuer)
     
     Common Stock
    (Title of Class of Securities)
     
     98420N105
    (CUSIP Number)
     
     December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    X Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     DRIEHAUS CAPITAL MANAGEMENT LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware, USA
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     4,345,180
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     4,345,180
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     4,345,180
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     5.88%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IA
     
     
     
     
     

    Item 1(a). Name of Issuer:

     Xenon Pharmaceuticals Inc.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

     200-3650 Gilmore Way, Burnaby
     British Columbia, Canada V5G 4W8

    Item 2(a). Name of Person Filing:

     DRIEHAUS CAPITAL MANAGEMENT LLC

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     25 East Erie Street
     Chicago, Illinois 60611

    Item 2(c). Citizenship:

     Delaware, USA

    Item 2(d). Title of Class of Securities:

     Common Stock
     
    Item 2(e). CUSIP Number:

      98420N105


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) X Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) Amount beneficially owned: 4,345,180


    (b) Percent of class: 5.88%


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote: 0


    (ii) Shared power to vote or to direct the vote: 4,345,180

      (iii) Sole power to dispose or to direct the disposition of: 0

      (iv) Shared power to dispose or to direct the disposition of: 4,345,180

    Footnote: This amendment is filed to reflect the change in our percentage of ownership of Xenon Pharmaceuticals, Inc. (XENE). DCM owned 5.88% of XENE as of December 31, 2023, down from 7.49% as of December 31, 2022.


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following X.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    N/A
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     N/A

    Item 8. Identification and Classification of Members of the Group.

     N/A

    Item 9. Notice of Dissolution of Group.

     N/A
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024
     
     
    DRIEHAUS CAPITAL MANAGEMENT LLC
     
     
    By:
     /s/ Janet McWilliams
       
    Name:  Janet McWilliams
       
    Title:  General Counsel
     
     
     

    Get the next $XENE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XENE

    DatePrice TargetRatingAnalyst
    5/7/2025$55.00Buy
    Chardan Capital Markets
    2/11/2025$67.00Buy
    Deutsche Bank
    10/10/2024$50.00Outperform
    Raymond James
    10/1/2024$53.00Buy
    H.C. Wainwright
    1/4/2024$62.00Buy
    Citigroup
    12/8/2023$63.00Outperform
    Robert W. Baird
    10/24/2023Overweight
    Cantor Fitzgerald
    4/25/2023$58.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $XENE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gannon Steven exercised 5,144 shares at a strike of $12.57, increasing direct ownership by 257% to 7,144 units (SEC Form 4)

      4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

      5/16/25 5:59:44 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT & CEO Mortimer Ian

      4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

      3/13/25 7:33:34 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Kenney Christopher John

      4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)

      3/13/25 7:31:01 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XENE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc.

      SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

      11/12/24 10:40:28 AM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

      2/14/24 9:12:03 AM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Xenon Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)

      2/14/24 7:43:11 AM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XENE
    SEC Filings

    See more
    • Xenon Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)

      6/5/25 5:07:40 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Xenon Pharmaceuticals Inc.

      10-Q - Xenon Pharmaceuticals Inc. (0001582313) (Filer)

      5/12/25 4:40:50 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xenon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)

      5/12/25 4:07:30 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XENE
    Financials

    Live finance-specific insights

    See more
    • Xenon Reports First Quarter 2025 Financial Results and Provides Business Update

      – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from completed Mount Sinai IST in MDD confirm azetukalner drug activity as seen in X-NOVA – Phase 1 study in healthy volunteers initiated for follow-on Kv7 channel opener XEN1120 – IND filing and Phase 1 study start for XEN1701, lead Nav1.7 candidate, anticipated in Q3 2025 – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-foc

      5/12/25 4:01:00 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xenon to Report Q1 2025 Financial Results on May 12, 2025

      VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025. Conference Call/Webcast Information:  Date:Monday, May 12, 2025  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Webcast:Pre-register here  Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference ID:5532604   A live webcast of t

      5/5/25 4:01:00 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

      – Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to initiate mid-year – Phase 3 azetukalner bipolar depression program planned for clinical trial initiation mid-year – Early-stage portfolio advancing with Kv7 and Nav1.7 IND filings anticipated in 2025 – Neurocrine collaboration achieves milestone with initiation of Phase 1 study of Nav1.2/Nav1.6 inhibitor – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.

      2/27/25 4:01:00 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XENE
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $XENE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

      VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025. Fireside Chat Presentation Details:  Date:Tuesday, June 10, 2025  Time:3:20-3:55 PM Eastern Time  Webcast:Register here  Presenter:Ian Mortimer, President and Chief Executive Officer   A live audio webcast of the company presentation will be available on the "Investors" sec

      6/3/25 4:01:00 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      VANCOUVER, British Columbia and BOSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 53,550 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of May 29, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

      5/30/25 4:01:00 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference

      VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 2025 RBC Capital Markets Global Healthcare Conference taking place in New York, NY from May 20-21, 2025. Fireside Chat Presentation Details: Date:  Wednesday, May 21, 2025 Time:  10:30-10:55 AM Eastern Time Webcast:  Register here Presenter:  Ian Mortimer, President and Chief Executive Officer A live audio webcast of the company presentation will be available on the "Inv

      5/14/25 4:01:00 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Xenon Pharmaceuticals with a new price target

      Chardan Capital Markets initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $55.00

      5/7/25 8:39:12 AM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Xenon Pharmaceuticals with a new price target

      Deutsche Bank initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $67.00

      2/11/25 7:18:40 AM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on Xenon Pharmaceuticals with a new price target

      Raymond James resumed coverage of Xenon Pharmaceuticals with a rating of Outperform and set a new price target of $50.00

      10/10/24 8:32:28 AM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XENE
    Leadership Updates

    Live Leadership Updates

    See more
    • Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

      – OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner – Approximately one in three patients on drug for at least 36 months achieved seizure freedom for a period of one year or longer – Sustained monthly reductions in seizure frequency maintained at 85% at OLE study month 36 – Patient-reported survey data and literature review illustrate significant mental health and comorbidity burdens of focal onset seizures highlighting areas of unmet need for people living with epilepsy – New pre-clinical data shows Nav1.1 potentiator provides protection against

      12/6/24 4:01:00 PM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer

      VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr. Ronsheim will lead Chemistry, Manufacturing and Controls (CMC), Program Management and Quality Assurance and as a member of the senior executive team will be responsible for providing strategic and operational leadership for the Company's pipeline of small molecule progr

      8/12/24 8:30:00 AM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary

      BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. Ms. DiFabio will provide strategic leadership and oversight of the planning and execution for Xenon's legal function on a global basis. Mr. Ian Mortimer, Xenon's President and Chief Executive Officer, stated, "We are very pleased to welcome Andrea to Xenon's senior leadership team in the newly created role of Chief Legal Officer. Andrea joins us at a time when we have multiple late-stage clinical programs underway with the

      11/7/22 8:30:00 AM ET
      $XENE
      Biotechnology: Pharmaceutical Preparations
      Health Care